The role of cholesterol and statins in stroke

Current Cardiology Reports

Volumn 11, Issue 1, 2009, Pages 4-11

  Navi, Babak B ^a   Segal, Alan Z ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD; HUMAN; HYPERCHOLESTEROLEMIA; PHYSIOLOGY; REVIEW; STROKE;

CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; STROKE;

EID: 63249108001     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-009-0002-3     Document Type: Article

References (54)

1. Iso H, Jacobs DR Jr, Wentworth D, et al.: Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the Multiple Risk Factor Interventional Trial. N Engl J Med 1989, 320:904-910. (Pubitemid 19101595)
2. Horenstein RB, Smith DE, Mosca L: Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002, 33:1863-1868. (Pubitemid 34761077)
3. Kurth T, Everett BM, Buring JE, et al.: Lipid levels and the risk of ischemic stroke in women. Neurology 2007, 68:556-562.
4. Prospective Studies Collaboration, Lewington S, Whitlock G, et al.: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 2007, 370:1829-1839. Important meta-analysis detailing weak epidemiologic link of cholesterol to stroke mortality.
5. Harmsen P, Lappas G, Rosengren A, Wilhelmsen L: Longterm risk factors for stroke. Twenty-eight years of follow-up of 7457 middle-aged men in Goteborg, Sweden. Stroke 2006, 37:1663-1667. (Pubitemid 44297709)
6. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ: Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005, 149:606-612.
7. Lindenstrom E, Boysen G, Nyboe J: Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994, 309:11-15.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 344:1383-1389.
9. Plehn JF, Davis BR, Sacks FM, et al.: Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) study. Circulation 1999, 99:216-223. (Pubitemid 29056362)
10. White HD, Simes J, Anderson NE, et al.: Pravastatin therapy and the risk of stroke. N Engl J Med 2000, 343:317-326. (Pubitemid 30616697)
11. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718. (Pubitemid 32259905)
12. La Rosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435. (Pubitemid 40471450)
13. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled trial. Lancet 2004, 364:685-696. (Pubitemid 39140624)
14. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003, 361:1149-1158. (Pubitemid 36398384)
15. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
16. Amarenco P, Bogousslavsky J, Callahan A III, et al.: Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559. Landmark study demonstrating the highly significant benefit of statins in secondary prevention of stroke. (Pubitemid 44202151)
17. Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis. Systematic review and up-to-date meta-analysis. Stroke 2004, 35:2902-2909. (Pubitemid 39565192)
18. Amarenco P, Goldstein LB, Szarek M, et al.: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007, 38:3198-3204. (Pubitemid 350175737)
19. Olsen TS, Christensen R H B, Kammersgaard LP, Andersen KK: Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality. Ten-year follow-up of ischemic strokes in the Copenhagen Stroke study. Stroke 2007, 38:2646-2651. (Pubitemid 47493998)
20. Curb JD, Abbott RD, Rodriguez BL, et al.: High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu Heart Program. Am J Epidemiol 2004, 160:150-157. (Pubitemid 38963001)
21. Amarenco P, Labreuche J, Touboul PJ: High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008, 196:489-496. Good review of association between HDL-C and stroke. (Pubitemid 351146660)
22. Barter P, Gotto AM, La Rosa JC, et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310. (Pubitemid 47481452)
23. Tirschwell DL, Smith NL, Heckbert SR, et al.: Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004, 63:1868-1875. (Pubitemid 39532383)
24. Laloux P, Galanti L, Jamart J: Lipids in ischemic stroke subtypes. Acta Neurol Belg 2004, 104:13-19. (Pubitemid 38559372)
25. Sanossian N, Saver JL, Kim D, et al.: Do high-density lipoprotein cholesterol levels influence stroke severity? J Stroke Cerebrovasc Dis 2006, 15:187-189. (Pubitemid 44332972)
26. Tanne D, Koren-Morag N, Graff E, Goldbout U: Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) registry: high triglycerides constitute an independent risk factor. Circulation 2001, 104:2892-2897. (Pubitemid 33139099)
27. Asia Pacific Cohort Studies Collaboration: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110:2678-2686.
28. Dziedzic T, Slowik A, Gryz EA, Szczudlik A: Lower serum triglyceride level is associated with increased stroke severity. Stroke 2004, 35:e151-e152.
29. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504. (Pubitemid 38477774)
30. Waters DD, La Rosa JC, Barter P, et al.: Effects of highdose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Ta r ge ts) st udy. J Am Coll Cardiol 2006, 48:1793-1799. (Pubitemid 44648630)
31. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
32. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
33. O'Regan C, Wu P, Arora P, et al.: Statin therapy in stroke prevention: a meta-analysis involving 121, 000 patients. Am J Med 2008, 121:24-33.
34. Collins R, Armitage J, Parish S, et al.: Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767.
35. Yano K, Reed DM, MacLean CJ: Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989, 20:1460-1465. (Pubitemid 19278129)
36. Sturgeon JD, Folsom AR, Longstreth WT Jr, et al.: Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 2007, 38:2718-2725. (Pubitemid 47494009)
37. Broderick JP, Diringer MN, Hill MD, et al.: Determinants of intracerebral hemorrhage growth. An exploratory analysis. Stroke 2007, 38:1072-1075. (Pubitemid 46568477)
38. Krysiak R, Okopien B, Herman Z: Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003, 63:1821-1854. (Pubitemid 37083030)
39. Henyan NN, Riche DM, East HE, Gann PN: Impact of statins on risk of stroke: a meta-analysis. Ann Pharmacother 2007, 41:1937-1945. (Pubitemid 350230560)
40. Goldstein LB, Amarenco P, Szarek M, et al.: Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008, 70:2364-2370. Important post hoc analysis of the SPARCL trial, detailing the increased risk of hemorrhagic stroke in patients receiving atorvastatin for secondary stroke prevention.
41. Bang OY, Saver JL, Liebeskind DS, et al.: Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007, 68:737-742. (Pubitemid 46667898)
42. Uyttenboogaart M, Koch MW, Koopman K, et al.: Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischemic stroke. J Neurol 2008, 255:875-880.
43. Cha J, Jeong M, Kim JW: Statin reduce the platelet p-selectin expression in atherosclerotic ischemic stroke. J Thromb Thrombolysis 2004, 18:39-42. (Pubitemid 40361647)
44. Endres M: Statins and stroke. J Cereb Blood Flow Metab 2005, 25:1093-1110. (Pubitemid 41710736)
45. Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235. (Pubitemid 29340127)
46. Shabanzadeh AP, Shuaib A, Wang CX: Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke. Brain Res 2005, 1042:1-5.
47. Hayashi T, Hamakawa K, Nagotani S, et al.: HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons. Brain Res 2005, 1037:52-58. (Pubitemid 40362381)
48. Prinz V, Laufs U, Gertz K, et al.: Intravenous rosuvastatin for acute stroke treatment. An animal study. Stroke 2008, 39:433-438. (Pubitemid 351619468)
49. Elkind MS, Flint AC, Sciacca RR, Sacco RL: Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005, 65:253-258. (Pubitemid 41022370)
50. Marti-Fabregas J, Gomis M, Arboix A, et al.: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004, 35:1117-1123.
51. Reeves MJ, Gargano JW, Luo Z, et al.: Effect of pretreatment with statins on ischemic stroke outcomes. Stroke 2008, 39:1779-1785. Influential paper revealing improved clinical outcome with statin therapy in acute ischemic stroke.
52. Montaner J, Chacon P, Krupinski J, et al.: Simvastatin in the acute phase off ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008, 15:82-90. (Pubitemid 350265291)
53. Colivicchi F, Bassi A, Santini M, Caltagirone C: Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007, 38:2652-2657. (Pubitemid 47493999)
54. Blanco M, Nombela F, Castellanos M, et al.: Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007, 69:904-910. Informative article demonstrating the deleterious effects of statin withdrawal in acute ischemic stroke. (Pubitemid 47329591)